Gedea Biotech develops pHyph ,an antibiotic-free treatment for vaginal infections. Today, bacterial vaginosis (BV) is treated with antibiotics and in a published clinical trial, pHyph shows similar cure rate as antibiotics; 82% cure rate after one week of treatment. With antibiotics, one out of two patients have a recurrent episode of BV within 90 days of treatment. The ongoing NEFERTITI-study is a placebo-controlled study with 150 patients with bacterial vaginosis, that investigates the efficacy and safety of pHyph in treatming and preventing bacterial vaginosis. pHyph intends be the first antibiotic-free treatment that effectively prevents and treats bacterial vaginosis.
Annette has a PhD in Medicine from Lund University and holds a Master’s degree in Medical Biology from Linköping University. She has long experience of project management and business development in both listed and unlisted companies also from the healthcare sector.
Did you know?
Gedea Biotech won third prize in the European Final of the EIT European Health Catapult, in the category of Biotech!